News on research and diagnostic development for pathogenic diseases.
In a wide-ranging discussion, the two leaders touched upon vaccine development, infant mortality, US education, research funding, machine learning, and precision medicine.
The firm hopes its newly launched DxWound will improve pathogen detection in skin and soft tissue infections by including anaerobic and fungal microbes in its reports.
Overall, the company reported its total revenues grew 29 percent year over year to $6.83 billion. It also said that it is reorganizing the Alere business, completed earlier this month.
The test detects and differentiates respiratory syncytial virus and human metapneumovirus on the firm's Solana rapid molecular platform.
The two companies plan to secure required initial regulatory approvals in individual African territories before expanding to other areas in the region.
